Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapering Ursodeoxycholic Acid in PBC Patients With Complete Response
NCT04650243Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2020
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ursodeoxycholic acid in primary biliary cholangitis (PBC) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Recurrence rate of primary biliary cholangitis at 12 months. Started Jan 2020; status: recruiting.
02
Drugs
ursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04650243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650243.